How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma? Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma dx.doi.org/10.1080/1750...

I enjoyed working with colleagues and mentors at Dartmouth to create and lead these workshops for medical students and faculty to develop skills in addressing microaggressions and bias in their roles as health care professionals, educators, and leaders. Learn more below👇 @aamctoday.bsky.social

At #Tandem25: @drkomanduri.bsky.social accepts the ASTCT advocacy award. Congratulations Dr. Komanduri, we commend you for your dedication to advancing our field!

Grateful to Clinical Lymphoma, Myeloma & Leukemia, co-authors, and @ash-hematology.bsky.social for the opportunity to share this research on targeted neurocognitive testing after anti-CD19 and anti-BCMA #CART cell therapy. #lymsm #mmsm clinical-lymphoma-myeloma-leukemia.com/article/S215...